High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin.
about
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potentDoxazolidine induction of apoptosis by a topoisomerase II independent mechanism.Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.Selective induction of apoptosis by the cytotoxic analog AN-207 in cells expressing recombinant receptor for luteinizing hormone-releasing hormone.Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice.Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.Mass spectrometric analysis of a cyclic 7,8-butanoguanine adduct of N-nitrosopyrrolidine: comparison to other N-nitrosopyrrolidine adducts in rat hepatic DNA.Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology.Peptide-mediated targeted drug delivery.Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer.Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model.Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.Evaluation of Apoptosis in Multipotent Hematopoietic Cells of Bone Marrow by Anthracycline Antibiotics.Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH.
P2860
Q24309593-E2BB7D2C-D049-446D-91B9-127494131B4AQ34056786-54945109-BEE7-4360-BCD7-583169B882F0Q34117185-1E9F7838-B405-495B-A23F-CC983B6F57D6Q34772221-7FEE9535-5F9B-446B-B4AD-0C49D28A10A2Q34840155-F5765EC0-107F-45C9-B1D3-8D2560F30797Q34979199-C8200D65-A255-48B7-92C3-3E1FB479091DQ35891113-3AC12F7E-607C-4DA3-8C0B-523BF4AAA95EQ35959684-78901E04-F180-4FDF-9F5A-1C3977277ED5Q35997236-FDE1D970-F5A6-4E3E-B31F-07FAF6FAB394Q36202016-67704D84-504E-4DC2-A3DC-59AB4B19C30DQ36619952-A39E91CC-E6B7-465C-A200-F8E3EAD17ECAQ36644341-C83D8BBF-AC91-484D-A8A8-7304176CC406Q37392272-7E759ACB-4BDC-43F7-8DA1-BB23A85A9A4AQ37579225-2981D0EB-5213-4444-ADA9-FE7B019BB235Q37785045-ED8616A7-E6E6-4847-BD08-B07493FC3487Q37859389-0CB46C83-606A-400D-868D-04432475ADE7Q38311828-CD37BCDF-A309-47B3-85DA-B67F52F33A73Q38882916-2B1B7737-82CF-4C91-B974-EBB1CF76452EQ39428786-27D18CE4-CDD3-4BB8-8B5B-3F24C21B3044Q40778582-2999B309-0961-47F8-989D-97B5ED5859D4Q46873284-F7283C80-4C7F-4959-9C7E-4DE1671DE647Q48656281-D79331E7-0B4E-4533-B92C-E6554E710DEA
P2860
High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
High yield conversion of doxor ...... ed derivatives of doxorubicin.
@en
High yield conversion of doxor ...... ed derivatives of doxorubicin.
@nl
type
label
High yield conversion of doxor ...... ed derivatives of doxorubicin.
@en
High yield conversion of doxor ...... ed derivatives of doxorubicin.
@nl
prefLabel
High yield conversion of doxor ...... ed derivatives of doxorubicin.
@en
High yield conversion of doxor ...... ed derivatives of doxorubicin.
@nl
P2860
P356
P1476
High yield conversion of doxor ...... ed derivatives of doxorubicin.
@en
P2093
P2860
P304
P356
10.1073/PNAS.93.6.2464
P407
P577
1996-03-01T00:00:00Z